Aegerion reported a loss of $0.20 per share in the third-quarter of
2014, wider than the Zacks Consensus Estimate for a loss of only
$0.18 but narrower than the year-ago loss of $0.43. Revenues of
$43.7 million missed the Zacks Consensus Estimate of $49 million.
We are disappointed with the company's lowered outlook for Juxtapid
sales this year. Additionally, the 2015 revenue outlook lags growth
expectations significantly. With Aegerion depending on Juxtapid for
growth, reimbursement issues and potential competition remain
matters of concern. We are remaining on the sidelines and
maintaining a Neutral recommendation on Aegerion.
Cambridge, MA-based Aegerion Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development of innovative
treatments for rare diseases.
Juxtapid (EU trade name: Lojuxta), Aegerion's only marketed
product, received FDA approval in Dec 2012 for the treatment of
homozygous familial hypercholesterolemia (HoFH). Aegerion is also
conducting a late-stage development program for the geographical
expansion of Juxtapid.
Juxtapid is approved in the U.S., the EU, Mexico, Canada, Norway
and Iceland. Aegerion generated net revenues of $48.5 million in
2013 consisting of Juxtapid sales.
Aegerion Pharmaceuticals, Inc. (AEGR): Read the
Full Research Report
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AEGERION PHARMA (AEGR): Free Stock Analysis
To read this article on Zacks.com click here.